AMPA potentiator treatment of cognitive deficits in Alzheimer disease

Neurology

Volumn 68, Issue 13, 2007, Pages 1008-1012

  Chappell, A S ^a   Gonzales, C ^a   Williams, J ^a   Witte, M M ^a   Mohs, R C ^a   Sperling, R ^b  

^a ELI LILLY AND COMPANY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR AGONIST; CHOLINESTERASE INHIBITOR; LORAZEPAM; LY 451395; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; INTERVIEW; LOW DRUG DOSE; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; QT INTERVAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIPHENYL COMPOUNDS; BRAIN; COGNITION DISORDERS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID AGONISTS; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; RECEPTORS, AMPA; SULFONAMIDES; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 34147116283     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000260240.46070.7c     Document Type: Article

References (25)

1. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998;37:1187-1204.
2. Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 2002;5(suppl):1035-1038.
3. Shepherd TA, Aikins JA, Bleakman D, et al. Design and synthesis of a novel series of 1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptors. J Med Chem 2002;45:2101-2111.
4. Toublanc N, Chalon S, Pereira A, Zhang L, Decourt JP, Chappell A. Single Dose Safety, Tolerance, and Pharmacokinetics of LY451395, an AMPA potentiator, in young healthy male subjects. 15th ECNP Congress, October 5-9, 2002, Barcelona Spain.
5. Chappell AS, Toublanc N, Jhee SS, Shiovitz T, Kim E. Multiple-dose safety and tolerability of LY450108 and LY451395 in patients with probable Alzheimer's disease (AD). Annual New Clinical Drug Evaluation Unit (NCDEU), June 10-13, 2002, Boca Raton, FL.
6. Pereira A, Chalon S, Cleton A, et al. Tolerability and pharmacokinetics of LY451395, a selective AMPA receptor potentiator, in healthy subjects and patients with probable Alzheimer's disease. 6th International Conference AD/PD, May 8-12, 2003, Seville, Spain.
7. Jhee SS, Chalon S, Toublanc N, et al. LY451395 cerebrospinal fluid pharmacokinetics in healthy human subjects. 31st annual meeting, American College of Clinical Pharmacology; September 21-23, 2002, San Francisco, CA, USA.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
11. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
12. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's Disease. A double-blind, placebo-controlled study. Mentane Study Group. Arch Intern Med 1995;155:1766-1772.
13. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 1999;6:423-429.
14. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
15. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
16. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.
17. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
18. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276.
19. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
20. Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997;146:553-559.
21. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21:484-487.
22. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurobiol 1997;145:89-92.
23. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-1031.
24. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000;19:1401-1409.
25. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Erratum appears in Br Med J 2001;322:405. Br Med J 2000;321:1445-1449.